Search clinical trials for: PF-06865571 Immediate release tablets

Total 796 results

Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Healthy Subjects

United States, Belgium
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Completed

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

United States
Pfizer

Completed

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Healthy

United States
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
Pfizer

Completed

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Healthy Volunteers

Belgium
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Pfizer

Completed

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

Biological Availability

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A SHR0302 BA Study on Healthy Subjects

Autoimmune Diseases

China
Guang'anmen Hospital of China Academy of Chinese...

Unknown

Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris

Coronary Heart Disease | Stable Angina
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

HIV Infections

United States, South Africa, Thailand, Botswana
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Pfizer

Withdrawn

A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

Migraine
Overseas Pharmaceuticals, Ltd.
Virginia Contract Research Organization Co., Ltd.

Terminated

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers

Pain Control

Taiwan
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Diurnal Limited
National Institutes of Health Clinical Center (CC)

Completed

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Adrenogenital Syndrome | Congenital Adrenal Hyperplasia | 21-Hydroxylase Deficiency

United States
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
Sarfez Pharmaceuticals, Inc.
Sarfez Pharmaceuticals, Inc.

Recruiting

Immediate Release Versus Extended Release Torsemide After Salty Meal

Heart Failure

United States
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Abbott

Completed

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

United States, Canada, Puerto Rico
AstraZeneca
Parexel

Completed

A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered

Sickle Cell Disease

Germany
ViiV Healthcare

Active, not recruiting

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

HIV Infections

United States, Thailand, Brazil, South Africa, Zimbabwe, Botswana, Tanzania

3

Subscribe